Leggy A Arnold

List of Publications by Year in Descending Order

96 papers	3,433 citations	30 h-index	56 g-index
116 ext. papers	3,755 ext. citations	5.4 avg, IF	4.63 L-index

#	Paper	IF	Citations
96	Development of Inhaled GABA Receptor Modulators to Improve Airway Function in Bronchoconstrictive Disorders.. *ACS Pharmacology and Translational Science*, **2022**, 5, 80-88	5.9	0
95	Strategies for the Design of Vitamin D Receptor Ligands **2021**, 199-217		
94	Assessment of Phenylboronic Acid Nitrogen Mustards as Potent and Selective Drug Candidates for Triple-Negative Breast Cancer. *ACS Pharmacology and Translational Science*, **2021**, 4, 687-702	5.9	0
93	Biological evaluation and synthesis of calcitroic acid. *Bioorganic Chemistry*, **2021**, 116, 105310	5.1	1
92	Targeting Nitric Oxide Production in Microglia with Novel Imidazodiazepines for Nonsedative Pain Treatment. *ACS Chemical Neuroscience*, **2020**, 11, 2019-2030	5.7	2
91	Nebulized MIDD0301 Reduces Airway Hyperresponsiveness in Moderate and Severe Murine Asthma Models. *ACS Pharmacology and Translational Science*, **2020**, 3, 1381-1390	5.9	1
90	Synthesis and biological evaluation of calcioic acid. *Steroids*, **2020**, 154, 108536	2.8	1
89	The Effects of pH on the Structure and Bioavailability of Imidazobenzodiazepine-3-Carboxylate MIDD0301. *Molecular Pharmaceutics*, **2020**, 17, 1182-1192	5.6	2
88	Improved scale-up synthesis and purification of clinical asthma candidate MIDD0301. *Organic Process Research and Development*, **2020**, 24, 1467-1476	3.9	5
87	A Structure-Activity Relationship Comparison of Imidazodiazepines Binding at Kappa, Mu, and Delta Opioid Receptors and the GABA Receptor. *Molecules*, **2020**, 25,	4.8	4
86	Design, synthesis and characterization of novel gamma-aminobutyric acid type A receptor ligands. *Arkivoc*, **2020**, 2020, 242-256	0.9	2
85	An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 126681	2.9	2
84	MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABA receptors without causing systemic immune suppression. *Basic and Clinical Pharmacology and Toxicology*, **2019**, 125, 75-84	3.1	6
83	Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles. *Molecular Neuropsychiatry*, **2019**, 5, 84-97	4.9	35
82	The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 3788-3796	3.4	3
81	Alternative binding sites at the vitamin D receptor and their ligands. *Molecular and Cellular Endocrinology*, **2019**, 485, 1-8	4.4	7
80	Design and Evaluation of Heterobivalent PAR1-PAR2 Ligands as Antagonists of Calcium Mobilization. *ACS Medicinal Chemistry Letters*, **2019**, 10, 121-126	4.3	8

79	A novel GABA receptor ligand MIDD0301 with limited blood-brain barrier penetration relaxes airway smooth muscle ex vivo and in vivo. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2019**, 316, L385-L390	5.8	9
78	Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the Aminobutyric Acid Type A Receptor (GABAR) Subtype with Improved Metabolic Stability and Enhanced Bioavailability. *Journal of Medicinal Chemistry*, **2018**, 61, 2422-2446	8.3	26
77	A high-throughput screening assay for pyruvate carboxylase. *Analytical Biochemistry*, **2018**, 550, 90-98	3.1	4
76	Novel VDR antagonists based on the GW0742 scaffold. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 351-354	2.9	7
75	A Novel Orally Available Asthma Drug Candidate That Reduces Smooth Muscle Constriction and Inflammation by Targeting GABA Receptors in the Lung. *Molecular Pharmaceutics*, **2018**, 15, 1766-1777	5.6	19
74	Identification of a novel, fast-acting GABAergic antidepressant. *Molecular Psychiatry*, **2018**, 23, 384-391	15.1	23
73	Modulating Vitamin D Receptor Coregulator Binding With Small Molecules **2018**, 657-666		1
72	Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents. *Journal of Medicinal Chemistry*, **2018**, 61, 9132-9145	8.3	23
71	Synthesis of chiral GABA receptor subtype selective ligands as potential agents to treat schizophrenia as well as depression. *Arkivoc*, **2018**, 2018, 158-182	0.9	7
70	Genetic and pharmacological manipulation of glyoxalase 1 regulates voluntary ethanol consumption in mice. *Addiction Biology*, **2017**, 22, 381-389	4.6	10
69	Pharmacological and antihyperalgesic properties of the novel 2/3 preferring GABA receptor ligand MP-III-024. *Brain Research Bulletin*, **2017**, 131, 62-69	3.9	20
68	Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for 2/3-containing GABA receptors. *Pharmacology Biochemistry and Behavior*, **2017**, 157, 35-40	3.9	19
67	Alleviation of Multiple Asthmatic Pathologic Features with Orally Available and Subtype Selective GABA Receptor Modulators. *Molecular Pharmaceutics*, **2017**, 14, 2088-2098	5.6	20
66	Optimization of substituted imidazobenzodiazepines as novel asthma treatments. *European Journal of Medicinal Chemistry*, **2017**, 126, 550-560	6.8	12
65	Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells. *European Journal of Medicinal Chemistry*, **2017**, 133, 197-207	6.8	18
64	New Oral Treatments for Asthma through Tissue-Specific Modulation of the GABAA Receptor. *Journal of Allergy and Clinical Immunology*, **2017**, 139, AB9	11.5	2
63	Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold. *ACS Combinatorial Science*, **2017**, 19, 646-656	3.9	3
62	Calcitroic Acid-A Review. *ACS Chemical Biology*, **2016**, 11, 2665-2672	4.9	21

61	Synthesis and Characterization of a Novel Aminobutyric Acid Type A (GABA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy. *Journal of Medicinal Chemistry*, **2016**, 59, 10800-10806	8.3	34
60	Inhibitors for the Vitamin D Receptor-Coregulator Interaction. *Vitamins and Hormones*, **2016**, 100, 45-82	2.5	4
59	Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites. *European Journal of Medicinal Chemistry*, **2016**, 109, 238-46	6.8	10
58	A New Pharmacological Approach for Asthma through Tissue-Specific Modulation of the GABA(A) Receptor. *Journal of Allergy and Clinical Immunology*, **2016**, 137, AB393	11.5	2
57	Development of GABAA Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma Treatments. *Molecular Pharmaceutics*, **2016**, 13, 2026-38	5.6	18
56	Characterization of GABA receptor ligands with automated patch-clamp using human neurons derived from pluripotent stem cells. *Journal of Pharmacological and Toxicological Methods*, **2016**, 82, 109-114	1.7	10
55	A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model. *International Journal of Medicinal Chemistry*, **2015**, 2015, 430248	1.7	31
54	Antitumor Activity of 3-Indolylmethanamines 31B and PS121912. *Anticancer Research*, **2015**, 35, 6001-7	2.3	7
53	A fluorescence-based high throughput assay for the determination of small molecule-human serum albumin protein binding. *Analytical and Bioanalytical Chemistry*, **2014**, 406, 1867-75	4.4	23
52	Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development. *Biochemical Society Transactions*, **2014**, 42, 461-7	5.1	15
51	Development of novel Vitamin D Receptor-Coactivator Inhibitors. *ACS Medicinal Chemistry Letters*, **2014**, 5, 199-204	4.3	20
50	Anticancer activity of VDR-coregulator inhibitor PS121912. *Cancer Chemotherapy and Pharmacology* , **2014**, 74, 787-98	3.5	16
49	IDENTIFICATION OF VDR ANTAGONISTS AMONG NUCLEAR RECEPTOR LIGANDS USING VIRTUAL SCREENING. *Nuclear Receptor Research*, **2014**, 1,	1.4	11
48	Modulation of Transcription mediated by the Vitamin D Receptor and the Peroxisome Proliferator-Activated Receptor in the presence of GW0742 analogs. *Journal of Biomolecular Research & Therapeutics*, **2014**, 3,		3
47	High-throughput identification of promiscuous inhibitors from screening libraries with the use of a thiol-containing fluorescent probe. *Journal of Biomolecular Screening*, **2013**, 18, 705-13		19
46	Peroxisome proliferation-activated receptor agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor. *Biochemistry*, **2013**, 52, 4193-203	3.2	19
45	PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models. *Genes and Cancer*, **2013**, 4, 524-34	2.9	8
44	Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. *Journal of Medicinal Chemistry*, **2012**, 55, 4640-51	8.3	40

43	Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays. *Nucleic Acids Research*, **2012**, 40, 8607-21	20.1	47
42	Comparison of cell expression formats for the characterization of GABA(A) channels using a microfluidic patch clamp system. *Assay and Drug Development Technologies*, **2012**, 10, 325-35	2.1	5
41	Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model. *PLoS ONE*, **2012**, 7, e34443	3.7	13
40	Similarities and differences between two modes of antagonism of the thyroid hormone receptor. *ACS Chemical Biology*, **2011**, 6, 1096-106	4.9	12
39	Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines. *Gynecologic Oncology*, **2011**, 123, 370-8	4.9	10
38	An integrated in‐vitro and in‐vivo high-throughput screen identifies treatment leads for ependymoma. *Cancer Cell*, **2011**, 20, 384-99	24.3	89
37	A quantitative high-throughput screen identifies novel inhibitors of the interaction of thyroid receptor beta with a peptide of steroid receptor coactivator 2. *Journal of Biomolecular Screening*, **2011**, 16, 618-27		15
36	Methylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone. *Journal of Biological Chemistry*, **2011**, 286, 11895-908	5.4	29
35	Ligand competition binding assay for the androgen receptor. *Methods in Molecular Biology*, **2011**, 776, 59-68	1.4	3
34	Differential regulation of epidermal function by VDR coactivators. *Journal of Steroid Biochemistry and Molecular Biology*, **2010**, 121, 308-13	5.1	20
33	Identification and characterization of the first small molecule inhibitor of MDMX. *Journal of Biological Chemistry*, **2010**, 285, 10786-96	5.4	152
32	Inhibition of a viral enzyme by a small-molecule dimer disruptor. *Nature Chemical Biology*, **2009**, 5, 640-6	11.7	72
31	Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 3892-901	8.3	44
30	Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. *ACS Chemical Biology*, **2009**, 4, 834-43	4.9	20
29	Quantification of the vitamin D receptor-coregulator interaction. *Biochemistry*, **2009**, 48, 1454-61	3.2	53
28	A high-throughput ligand competition binding assay for the androgen receptor and other nuclear receptors. *Journal of Biomolecular Screening*, **2009**, 14, 43-8		16
27	Synthesis and characterization of BODIPY-labeled colchicine. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5867-70	2.9	7
26	Interaction between the androgen receptor and a segment of its corepressor SHP. *Acta Crystallographica Section D: Biological Crystallography*, **2007**, 63, 1198-200		16

25	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. *Journal of Medicinal Chemistry*, **2007**, 50, 5269-80	8.3	38
24	A surface on the androgen receptor that allosterically regulates coactivator binding. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 16074-9	11.5	229
23	Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. *Molecular Endocrinology*, **2007**, 21, 2919-28		53
22	A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. *Science Signaling*, **2006**, 2006, pl3	8.8	23
21	Synthesis of highly substituted dibenzo[b,f]azocines and their evaluation as protein kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5360-3	2.9	15
20	Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. *Journal of Biological Chemistry*, **2005**, 280, 43048-55	5.4	88
19	Highly Enantioselective Copper-Catalyzed Allylic Alkylation with Phosphoramidite Ligands. *Advanced Synthesis and Catalysis*, **2004**, 346, 413-420	5.6	71
18	Synthesis of medium ring heterocycles using an intramolecular Heck reaction. *Organic Letters*, **2004**, 6, 3005-7	6.2	77
17	Catalytic enantioselective synthesis of (-)-prostaglandin E1 methyl ester based on a tandem 1,4-addition-aldol reaction. *Journal of Organic Chemistry*, **2002**, 67, 7244-54	4.2	86
16	Copper phosphoramidite catalyzed enantioselective ring-opening of oxabicyclic alkenes: remarkable reversal of stereocontrol. *Organic Letters*, **2002**, 4, 2703-5	6.2	124
15	New bidentate chiral phosphoramidites in copper-catalyzed asymmetric 1,4-addition of diethylzinc to cyclic enones: enantioselective tandem 1,4-addition-aldol reactions with 2-cyclopentenone. *Tetrahedron: Asymmetry*, **2001**, 12, 1929-1937		38
14	Highly Enantioselective Copper–Phosphoramidite Catalyzed Kinetic Resolution of Chiral 2-Cyclohexenones. *Angewandte Chemie*, **2001**, 113, 953-956	3.6	16
13	Highly Enantioselective Copper-Phosphoramidite Catalyzed Kinetic Resolution of Chiral 2-Cyclohexenones. *Angewandte Chemie - International Edition*, **2001**, 40, 927-930	16.4	70
12	Enantioselective synthesis of bicyclic compounds via catalytic 1,4-addition-ring closing metathesis. *Chemical Communications*, **2001**, 735-736	5.8	32
11	Catalytic enantioselective synthesis of prostaglandin E(1) methyl ester using a tandem 1,4-addition-aldol reaction to a cyclopenten-3,5-dione monoacetal. *Journal of the American Chemical Society*, **2001**, 123, 5841-2	16.4	104
10	Enantioselective copper-catalyzed allylic alkylation with dialkylzincs using phosphoramidite ligands. *Organic Letters*, **2001**, 3, 1169-71	6.2	100
9	Enantioselective Catalytic Conjugate Addition of Dialkylzinc Reagents using Copper–Phosphoramidite Complexes; Ligand Variation and Non-linear Effects. *Tetrahedron*, **2000**, 56, 2865-2878	2.4	257
8	A new catalytic and enantioselective desymmetrization of symmetrical methylidene cycloalkene oxides. *Organic Letters*, **2000**, 2, 933-6	6.2	27

7	A new diastereo- and enantioselective copper-catalyzed conversion of alkynyl epoxides into allenic alcohols. *Tetrahedron Letters*, **1999**, 40, 4893-4896	2	42
6	Catalytic Enantioselective Annulations via 1,4-Addition–Aldol Cyclization of Functionalized Organozinc Reagents. *Journal of the American Chemical Society*, **1999**, 121, 1104-1105	16.4	134
5	Catalytic enantioselective carbon?carbon bond formation by addition of dialkylzinc reagents to cyclic 1,3-diene monoepoxides. *Tetrahedron Letters*, **1998**, 39, 7795-7798	2	44
4	Highly Enantioselective Catalytic Conjugate Addition and Tandem Conjugate Addition–Aldol Reactions of Organozinc Reagents. *Angewandte Chemie International Edition in English*, **1997**, 36, 2620-2623		396
3	Hochenantioselektive katalytische 1,4-Addition und kombinierte 1,4-Addition/Aldolreaktion von Organozinkreagentien an Enone. *Angewandte Chemie*, **1997**, 109, 2733-2736	3.6	91
2	Copper-catalyzed Enantioselective Conjugate Addition Reactions of Organozinc Reagents224-258		39
1	Targeting Vitamin-D receptor (VDR) by a small molecule antagonist MeTC7 inhibits PD-L1 but controls THMYCN neuroblastoma growth PD-L1 independently		1